Rob Brierley
LightNews LightNews
banner
robbrierley.bsky.social
Rob Brierley
@robbrierley.bsky.social
1.3K followers 530 following 300 posts
Editor-in-Chief, The Lancet Gastroenterology & Hepatology @lancetgastrohep.bsky.social.

Views my own; reposting ≠ endorsement. #GastroSky #LiverSky #GISky #OncSky
Posts Replies Media Videos
Reposted by Rob Brierley
lancetimaging.bsky.social
🚀 Just launched – our new #goldopenaccess journal on medical imaging and theranostics!
Learn more about the journal’s mission and explore related content from The Lancet Group today: hubs.li/Q041CgFF0

#medsky
Announcing The Lancet Medical Imaging & Theranostics. A new open access journal dedicated to clinical and technological advances in radiology, neuclear medicine, and theranostics. Artwork: Abstract medical image of a torso with vibrant organic shapes and geometric patterns, suggesting medical imaging. Credit: Shonagh Rae
February 5, 2026 at 5:29 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research: Long-term oncological outcomes following algorithm-based vs usual care for the early recognition & management of complications after pancreatic resection: post-hoc analysis of a stepped-wedge cluster-randomised trial

www.thelancet.com/journals/lan...

#GastroSky #OncSky #MedSky
February 7, 2026 at 10:28 AM
robbrierley.bsky.social
EMA grants conditional marketing authorisation for semaglutide for treatment of non-cirrhotic MASH with liver fibrosis

#LiverSky #MedSky
ema.europa.eu European Medicines Agency @ema.europa.eu · 8d
📢 EMA recommends: 6 new medicines 💊 for approval, including the first #GLP1 #medicine indicated for a serious liver disease and an extension of indication to the first emergency nasal spray for allergies in children.
#PublicHealth #medsky
www.ema.europa.eu/en/news/meet...
January 30, 2026 at 1:56 PM
robbrierley.bsky.social
NHS England to lower threshold for the amount of blood detected by FIT that triggers further investigation from 120 to 80 micrograms of blood/g of stool by 2028

www.theguardian.com/society/2026...

#GastroSky #MedSky #OncSky
NHS to increase accuracy of bowel cancer test in England
Increased sensitivity of test that detects the second deadliest cancer will save hundreds of lives, oncologists say
www.theguardian.com
January 26, 2026 at 8:27 AM
Reposted by Rob Brierley
thelancetinfdis.bsky.social
New Research

Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study

www.thelancet.com/journals/lan...
Safety and efficacy of CRS3123 in adults with a primary episode or first recurrence of Clostridioides difficile infection: a phase 2, randomised, double-blind, multicentre, vancomycin-controlled study
Both doses of CRS3123 were deemed safe and well tolerated and showed efficacy similar to vancomycin at the TOC visit, with lower rates of recurrence. Together, these data support further development o...
www.thelancet.com
January 23, 2026 at 8:17 AM
robbrierley.bsky.social
Guinea-Bissau Suspends Trump-Backed Hep B Vaccine Trial for Ethical Review www.medpagetoday.com/infectiousdi...

#LiverSky #IDSky #HepSky #MedSky
Guinea-Bissau Suspends Trump-Backed Hep B Vaccine Trial for Ethical Review
But HHS spokesman says the study 'is proceeding as planned'
www.medpagetoday.com
January 23, 2026 at 9:58 AM
Reposted by Rob Brierley
thelancetrheum.bsky.social
NEW RESEARCH—Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial bit.ly/4pSERqq

Plus, linked Comment bit.ly/49v27Ga #Medsky #Rheumsky
January 21, 2026 at 9:56 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
News - ASCO Gastrointestinal Cancers Symposium 2026

www.thelancet.com/journals/lan...

#GI26 #ASCOGI #GastroSky #OncSky #MedSky
ASCO Gastrointestinal Cancers Symposium 2026
A prespecified interim analysis of HERIZON-GEA-01 indicates that zanidatamab—a dual HER2-targeted monoclonal antibody that crosslinks neighbouring HER2 receptors and causes receptor clustering—might b...
www.thelancet.com
January 21, 2026 at 8:15 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New review - Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis

www.thelancet.com/journals/lan...

#GastroSky #MedSky
Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis
Small intestinal microbial dysbiosis (SIMD) describes clinical syndromes attributed to overabundance of microbes within the small intestine. Usually attributed to bacteria (but also less commonly to a...
www.thelancet.com
January 15, 2026 at 11:14 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New Comment - Menopause and inflammatory bowel disease: more questions than answers

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky
January 16, 2026 at 9:15 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
Controversial CDC-Funded Hep B Study Halted www.medpagetoday.com/infectiousdi...
Controversial CDC-Funded Hep B Study Halted
An official from the Africa CDC said if it moves forward, it must meet ethical criteria
www.medpagetoday.com
January 16, 2026 at 11:01 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial

www.thelancet.com/journals/lan...

#HepSky #IDSky #LiverSky #MedSky
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial
ALG-000184 was safe and well tolerated, demonstrated predictable pharmacokinetic properties, and reduced HBV DNA and HBV RNA at all doses regardless of HBeAg status. These results support the evaluati...
www.thelancet.com
January 19, 2026 at 4:55 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial

www.thelancet.com/journals/lan...

#GastroSky #MedSky #IBDSky
Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised contr...
C-EEN was superior to PEN in maintaining clinical remission over 1 year in paediatric patients with Crohn's disease responding to EEN induction therapy. These findings suggest a new way to use nutriti...
www.thelancet.com
January 20, 2026 at 2:31 PM
Reposted by Rob Brierley
thelancet.com
Disorders of the gastrointestinal tract can have a major impact on individuals' wellbeing, nutrition, and quality of life.

In @lancetgastrohep.bsky.social, authors summarise current knowledge of age-related changes of the gastrointestinal tract: spkl.io/63325AWxGS
Figure: Age-related changes of the gastrointestinal tract. Copyright: 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
January 13, 2026 at 3:08 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

www.thelancet.com/journals/lan...

#GastroSkt #MedSky #IBDSky
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-contr...
Subcutaneous guselkumab induction and maintenance was safe and efficacious for 24 weeks in participants with moderately to severely active ulcerative colitis, establishing a fully subcutaneous guselku...
www.thelancet.com
January 14, 2026 at 8:04 AM
Reposted by Rob Brierley
ebiomedicine.bsky.social
📢 Our first issue of 2026 is now live! The latest issue highlights cutting-edge research in gene therapy, immunology, neuroscience, and translational medicine.

🔗 Read the full issue online
eBioMedicine January 2026 cover. The cover depicts scientists on ladders and scaffolds working on a strand of DNA.
January 14, 2026 at 2:28 PM
Reposted by Rob Brierley
thelancet.com
Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease.

In @lancetgastrohep.bsky.social, a new Review summarises recent breakthroughs and potential future developments: spkl.io/63326Amv4o
Figure summarising the mechanisms of action targeted for MASH therapy. MASH=metabolic dysfunction-associated steatotic liver disease. Copyright: 2025 Elsevier Ltd. All rights are reserved.
January 8, 2026 at 12:36 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study

www.thelancet.com/journals/lan...

#IBD #GastroSky #MedSky
January 7, 2026 at 9:57 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
Our Feb 2026 issue is now live at www.thelancet.com/gastrohep!

Content includes #colorectalcancer, paediatric #ulcerativecolitis, #cholangiocarcinoma, #viralhepatitis, #MASH + more…

#GastroSky #LiverSky #MedSky #OncSky
January 7, 2026 at 7:38 AM
Reposted by Rob Brierley
thelancetendo.bsky.social
Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment
www.thelancet.com/journals/lan...
#MASLD #obesity #lipodystrophy
#OpenAccess

#MedSky #EndoSky #LiverSky
December 14, 2025 at 12:33 PM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New Editorial - ACIP’s HBV birth-dose vaccine recommendations: a fiasco

www.thelancet.com/journals/lan...

#HepSky #LiverSky #MedSky #IDSky
www.thelancet.com
December 16, 2025 at 11:45 PM
Reposted by Rob Brierley
thelancetinfdis.bsky.social
Read our January issue!

Featuring Sotrovimab in hospitalised COVID-19 patients, global policy responses to antimicrobial resistance, and evaluating dengue vaccination in Brazilian adolescents

www.thelancet.com/issue/S1473-...
December 18, 2025 at 9:27 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
It's time for our end-of-year round up of highlights from @lancetgastrohep.bsky.social!

www.linkedin.com/posts/langas...

#GastroSky #MedSky #LiverSky #IDSky #EndoSky
#gastroenterology #hepatology #medicine #healthcare | The Lancet Gastroenterology & Hepatology
It's that time of the year when the Editors of The Lancet Gastroenterology & Hepatology pick their highlights from the past year! 1) A fantastic review of the intestinal barrier and its role in disea...
www.linkedin.com
December 18, 2025 at 11:41 AM
Reposted by Rob Brierley
lancetgastrohep.bsky.social
New research - Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12Cmutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials

www.thelancet.com/journals/lan...

#GastroSky #OncSky #MedSky
December 2, 2025 at 6:27 AM